56 results
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
7 May 24
Rhythm Pharmaceuticals Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
7:10am
. Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic … .
Setmelanotide Indication
In the United States, setmelanotide is indicated for chronic weight management in adult and pediatric patients 6 years of age
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
1 Apr 24
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
5:25pm
(setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) for chronic … .
Setmelanotide Indication
In the United States, setmelanotide is indicated for chronic weight management in adult and pediatric patients 6 years of age
424B5
RYTM
Rhythm Pharmaceuticals Inc.
29 Feb 24
Prospectus supplement for primary offering
4:44pm
Britain, Canada and other countries and regions. IMCIVREE is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management … in the United States, European Union (EU) and Great Britain. IMCIVREE is approved by the U.S. Food and Drug Administration (FDA) for chronic weight
8-K
EX-99.1
0481mvo7
22 Feb 24
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
7:01am
8-K
EX-99.1
rkrwlw i92
7 Nov 23
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
bf1x 7poil6l1
1 Aug 23
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business
7:05am
8-K
EX-99.1
6056b 778
2 May 23
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
hgcjlum5z 6t2vbc2
8 Nov 22
Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update
7:03am
424B5
b68w nujqau7unfwkrmw
15 Sep 22
Prospectus supplement for primary offering
4:00pm
424B5
c2qpm
14 Sep 22
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
5recaw7u jvc2q6
2 Aug 22
Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update
7:02am
8-K
EX-99.1
asmkyb 7vqc
3 May 22
Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update
7:05am